What is Okomera?
Okomera operates at the intersection of biotechnology and advanced engineering, specializing in the integration of standard assays on-chip. By streamlining complex processes such as CRISPR screening, T-cell analysis, and cytotoxicity testing, the company provides a robust framework for pharmaceutical developers to enhance the predictivity of their preclinical pipelines. This technological approach effectively bridges the gap between initial target identification and clinical validation, reducing the time and cost associated with bringing life-saving oncology treatments to market. Their platform is designed to handle high-throughput requirements, ensuring that researchers can iterate rapidly while maintaining high data fidelity.
How much funding has Okomera raised?
Okomera has raised a total of $1.6M across 1 funding round:
Grant
$1.6M
Grant (2024): $1.6M with participation from Institut Paoli-Calmettes
Key Investors in Okomera
Institut Paoli-Calmettes
Institut Paoli-Calmettes is a prominent cancer care center and research institution based in France, dedicated to advancing medical knowledge and training specialists in oncology.
What's next for Okomera?
With this major strategic investment, Okomera is well-positioned to transition from its current development phase into a broader commercial expansion. The capital will likely be deployed to enhance manufacturing capabilities for its lab-on-a-chip systems and to expand its collaborative footprint with global pharmaceutical partners. As the industry shifts toward more precise, data-driven drug development, Okomera's ability to provide scalable, automated assay solutions will be critical. Future growth will likely focus on deepening its oncology research capabilities and potentially diversifying its assay portfolio to address a wider range of therapeutic areas, ensuring the company remains at the forefront of the biotech innovation ecosystem.
See full Okomera company page
